Brazilian study to uncover genetic clues behind stroke

NCT ID NCT07186517

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study will look at the genes of 1,000 people in Brazil—half who had a stroke and half who did not—to find genetic differences that may increase stroke risk. Researchers will use whole genome sequencing to analyze DNA and compare it with international data. The goal is to better understand stroke in Brazil's diverse population and lay the groundwork for personalized medicine in the future.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors predict stroke risk based on a person's genetics, leading to more personalized prevention and treatment.
What could go wrong
This is an observational study, not a treatment trial. It may not find clear genetic links, and results may not apply to other populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,000 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2025

An estimate. Start dates often move.

Expected to finish

Dec 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

500 ischemic stroke patients and 500 controls with no family or personal history of stroke.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Cases * Age ≥18 years; * Confirmed diagnosis by neuroimaging (CT or MRI) of a first episode of ischemic stroke in the last 12 months; * TOAST classification of stroke available: cardioembolic, lacunar, atherosclerotic, or undetermined due to the presence of multiple sources (cardioembolic/atherosclerotic); * Modified Rankin Scale (mRS) ≤4 at the time of inclusion; * Ability and willingness to provide consent and participate in follow-up assessments. Controls * Age ≥18 years; * Reside in the same household or, if not, in the same neighborhood as the case group participant; * Not be a blood relative of the case group participant; * Ability and willingness to provide consent and participate in follow-up assessments. Exclusion Criteria: Cases * Ischemic stroke with a distinct etiology based on TOAST criteria (e.g., infectious, autoimmune, endocarditis, reversible cerebral vasoconstriction syndrome, drug-related causes); * Diagnosis of monogenic or mitochondrial disorders, such as CADASIL, Fabry disease, homocystinuria, MELAS, sickle cell disease, among others; * Clinical conditions that reduce life expectancy to less than one year (e.g., neoplasia); * Inability to undergo magnetic resonance imaging (due to metal artifacts, MRI-incompatible implants, claustrophobia); * Other conditions that, at the investigator's discretion, prevent participation or compromise follow-up. Controls * Personal history of stroke, transient ischemic attack (TIA), coronary, or peripheral artery disease; * Serious comorbidities that may impact participation or confound the results; * Clinical conditions that reduce life expectancy to less than one year; * Inability to provide consent due to cognitive impairment or other factors; * Inability to undergo magnetic resonance imaging (due to metal artifacts, incompatible implants, claustrophobia); * Diagnosis of monogenic or mitochondrial disorders, such as CADASIL, Fabry disease, homocystinuria, MELAS, or sickle cell disease; * Other conditions that, at the investigator's discretion, prevent participation or compromise follow-up.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Genetic association studies are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    11 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Clínica Neurológica

    Joinville, Brazil

  • Hospital Geral de Fortaleza

    Fortaleza, Brazil

  • Hospital Geral de Palmas

    Palmas, Brazil

  • Hospital Geral de Roraima

    Boa Vista, Brazil

  • Hospital Metropolitano Dr. Célio de Castro

    Belo Horizonte, Brazil

  • Hospital Ophir Loyola

    Belém, Brazil

  • Hospital São Paulo

    São Paulo, Brazil

  • Hospital Universitário Edgar Santos

    Salvador, Brazil

  • Hospital Universitário Maria Aparecida Pedrossian

    Campo Grande, Brazil

  • Hospital da Restauração Governador Paulo Guerra

    Recife, Brazil

  • Hospital de Clínicas de Porto Alegre

    Porto Alegre, Rio Grande do Sul, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.